PHARMACOLOGICAL ACTIVATION OF AMPK INHIBITS INCISION-EVOKED MECHANICAL HYPERSENSITIVITY AND THE DEVELOPMENT OF HYPERALGESIC PRIMING IN MICE

MICHAEL D. BURTON, a DiPTI V. TILLU a,b
KHADIJAH MAZHAR, a GALO L. MEJIA, a,b
MARINA N. ASIEDU, a,b KUFREOBONG INYANG, a
TRAVIS HUGHES, a BO LIAN, a GREGORY DUSSOR a,b
AND THEODORE J. PRICE a,b

a School of Behavioral and Brain Sciences, The University of Texas at Dallas, 800W. Campbell Rd, Richardson, TX 75080, USA
b University of Arizona, Department of Pharmacology, Tucson, AZ 85721, USA

Abstract—New therapeutics to manage post-surgical pain are needed to mitigate the liabilities of opioid and other analgesics. Our previous work shows that key modulators of excitability in peripheral nociceptors, such as extracellular signal-regulated kinases (ERK) are inhibited by activation of adenosine monophosphate activated protein kinase (AMPK). We hypothesized that AMPK activation would attenuate acute incision-evoked mechanical hypersensitivity and the development of hyperalgesic priming caused by surgery in mice. Here we have used a variety of administration routes and combinations of AMPK activators to test this hypothesis. Topical administration of a resveratrol-based cream inhibited acute mechanical hypersensitivity evoked by incision and blocked the development of hyperalgesic priming. We also observed that systemic administration of metformin dose-dependently inhibited incision-evoked mechanical hypersensitivity and hyperalgesic priming. Interestingly, low doses of systemic metformin and local resveratrol that had no acute effect were able to mitigate development of hyperalgesic priming. Combined treatment with doses of systemic metformin and local resveratrol that were not effective on their own enhanced the acute efficacy of the individual AMPK activators for post-surgical mechanical pain alleviation and blocked the development of hyperalgesic priming. Finally, we used dorsal root ganglion (DRG) neurons in culture to show that resveratrol and metformin given in combination shift the concentration–response curve for AMPK activation to the left and increase the magnitude of AMPK activation. Therefore, we find that topical administration is an effective treatment route of administration and combining systemic and local treatments led to anti-nociceptive efficacy in acute mechanical hypersensitivity at doses that were not effective alone. Collectively our work demonstrates a specific effect of AMPK activators on post-surgical pain and points to novel therapeutic opportunities with potential immediate impact in the clinical setting. © 2017 IBRO. Published by Elsevier Ltd. All rights reserved.

Key words: AMPK, metformin, resveratrol, plantar incision, topical therapeutics.

INTRODUCTION

One out of four chronic pain patients suffer from persistent pain because of prior surgery (Crombie et al., 1998) and up to 50% of patients who undergo common surgical procedures develop chronic pain (Kehlet et al., 2006; Johansen et al., 2012). Surgery remains a major cause of persistent pain despite the fact that analgesics for the treatment of acute post-surgical pain are widely available. This suggests that treatments targeting the molecular pathology to prevent or block the transition to chronic post-surgical pain are needed. New ways to interfere with acute post-surgical pain are also needed given the growing negative impact of opioids on society (Skolnick and Volkow, 2016; Volkow and Collins, 2017). While there have been advances in our understanding of signaling pathways and mediators that play an important role in driving post-surgical pain (Velinar et al., 2009; Ling et al., 2017), treatment approaches that target these pathways or mediators are currently not clinically utilized.

In animal models of post-surgical pain, there is an increase in interleukin 6 (IL-6) and nerve growth factor (NGF) levels in serum and skin around the incision site, which signal through the ERK and mechanistic target of rapamycin (mTOR) pathways inducing nociceptive sensitization (Matsuda et al., 1998; Sato and Ohshima, 2000; Banik et al., 2005; Bryan et al., 2005). We have shown that both of these pathways are negatively regulated by adenosine monophosphate (AMP)-activated protein kinase (AMPK) in nociceptors (Melemdjian et al., 2010; Tillu et al., 2012b; Mejia et al., 2016). AMPK is a ubiquitous energy sensing kinase, activated by an increase in intracellular AMP/ATP ratio during energy deprivation. The anti-diabetic drug metformin activates AMPK indirectly via inhibition of mitochondrial complex I (Owen et al., 2000; Shaw et al., 2005) or via inhibition of AMP deaminase (Ouyang et al., 2011). Both of these mechanisms lead to increased AMP levels in cells which allosterically activates AMPK (Hardie, 2015). Resveratrol activates AMPK through multiple mechanisms, but its...
mechanism of action in neurons appears to be distinct. In neuronal-like cell lines, and cortical and DRG neurons resveratrol does not alter AMP/ATP cellular ratios but activates AMPK via a mechanism that requires the upstream kinase liver kinase B1 (LKB1) (Dasgupta and Milbrandt, 2007), which phosphorylates the α subunit of AMPK to increase kinase activity (Shaw et al., 2005). We have demonstrated that the AMPK activators, metformin, A769662, and R419 inhibited translation regulation signaling pathways and nascent protein synthesis in DRG neurons resulting in a resolution of neuropathic allodynia induced by peripheral nerve injury, in the case of metformin and A769662 (Melemedjian et al., 2011), or incision-evoked mechanical pain in the case of R419 (Mema et al., 2016). Additionally, we demonstrated that resveratrol profoundly inhibited ERK and mTOR signaling in sensory neurons in a time- and dose-dependent fashion and local injection of resveratrol around the surgery site attenuated surgery-induced mechanical hypersensitivity in a model of post-surgical pain (Tillu et al., 2012b).

The aim of the present study was to further establish AMPK activation as a mechanism for the prevention of post-surgical persistent pain states and to introduce novel therapeutics and therapeutic strategies that employ this mechanism of action for use in humans. To do this, we utilized multiple AMPK activators and administration routes, including topical and local resveratrol, as well as systemic metformin. Our experimental endpoint was incision-induced mechanical hypersensitivity and hyperalgesic priming in mice where we observed efficacy for the attenuation of acute mechanical hypersensitivity and prevention of development of hyperalgesic priming.

**EXPERIMENTAL PROCEDURES**

**Experimental animals**

Male ICR mice (Envigo, 20–25 g) were used for the study. All animal procedures were approved by the Institutional Animal Care and Use Committee of The University of Texas at Dallas and University of Arizona and were in accordance with International Association for the Study of Pain guidelines. Mice were used in behavioral experiments starting one week after arrival at the animal facility at University of Texas at Dallas. Animals were housed with a 12-h light/dark cycle and had food and water available ad libitum.

**Behavioral testing conditions**

For behavioral testing, animals were placed in acrylic boxes with wire mesh floors and allowed to habituate for approximately 1 h on all testing days. Paw withdrawal thresholds were measured using calibrated von Frey filaments (Stoelting) by stimulating the plantar aspect of left hind paw using the up–down method (Chaplan et al., 1994).

**Plantar incision, behavioral testing, and treatments**

Prior to surgery all animals were assessed for baseline paw withdrawal thresholds. A mouse model of plantar incisional pain was used for this study (Banik et al., 2006). A 5 mm longitudinal incision was made with a number 11 blade through skin, fascia, and muscle of the plantar aspect of the left hindpaw in anesthetized animals (1% isofluorane). The skin was closed with 2 sutures of 5-mm silk. The sutures were removed 48 h later. Animals were allowed to recover for 24 h and then paw withdrawal thresholds were measured at several time-points (1, 2, 3, 4, 5, 6, 10, 11 and 14 days) post-surgery. For hyperalgesic priming experiments, the animals received an intraplantar injection of prostaglandin E2 (PGE2) (100 ng/25 μl) 14 or more days following incision when they had completely returned to baseline mechanical thresholds (Asiedu et al., 2011). The paw withdrawal thresholds were again measured at 3 h and 24 h following the PGE2 injection. For topical cream preparation with resveratrol (Cayman chemical), lyophilized resveratrol was serially dissolved in polyethylene glycol 400 (PEG 400) and solid PEG ointment to achieve a final concentration of 2 mg/ml. For experiments with topical resveratrol, mice were maintained under anesthesia (1% isofluorane) for 1 h to allow for absorption of the topically applied cream into the skin at times indicated immediately after the incision and 1-day post incision. For local injection treatments, animals received a 25 μl intraplantar injection of resveratrol (Cayman chemical) (1 or 3 μg) or vehicle immediately after surgery and 1-day post incision. Mice were not anesthetized for these injections and were only anesthetized briefly for incision, again with isofluorane. For systemic treatments, animals received an intraperitoneal (IP) injection of freshly prepared metformin (LKT laboratories, 30, 100, 150, or 200 mg/kg) for 4 days; 2 days before surgery, the day of surgery, and 1-day post surgery. The experimenters measuring mechanical withdrawal thresholds were always blinded to the experimental conditions. Mice were randomized to groups by a blinded experimenter and mice of individual groups were never housed together (e.g. home cages were always mixed between experimental groups).

**Tissue culture for cellular imaging**

Dorsal root ganglia (DRG) were extracted aseptically from 5 to 12 4-week old male ICR mice per cell culture plate for each cellular imaging experiment and placed in Hank’s Buffered Salt Solution (HBSS, Invitrogen) on ice. The ganglia were dissociated enzymatically at 37 °C; first with collagenase A (1 mg/ml, Roche) for 25 min, then collagenase D (1 mg/ml, Roche) that included papain (30 μg/ml, Roche) for 20 min. Afterward, a trypsin inhibitor (1 mg/ml, Roche) that contained bovine serum albumin (BSA, Fisher, 1 mg/ml) was applied and the ganglia were mixed to allow for further dissociation with a polished Pasteur pipette. The tissue was then filtered through 70-μm nylon cell strainer ( Falcon) and resuspended in DMEM F-12 Glutamax media (Invitrogen) that contained 10% fetal bovine serum (FBS, Hyclone) and 1× penicillin streptomycin (Pen-Strep). The media also contained NGF (10 ng/ml, Millipore) and 5-fluoro-2′-deoxyuridine + uridine (FRDU-U, 3.0 μg/ml + 7.0 μg/ml, Sigma) to reduce proliferation of glia and fibroblasts. Neurons were cultured for three-five days on 12-mm
glass coverslips (#1 thickness, Chemglass) in a 24-well tissue culture plate (Falcon) coated with poly-o-lysine (Sigma) at 37 °C with 95% air and 5% CO₂. The day before the experiment, FRDU-U was removed from the media and excluded. On the day of the experiment, drugs were diluted into DMEM F-12 plus GlutaMax media and added directly onto the neurons at a 10x concentration without any wash.

**Immunocytochemistry (ICC) and image analysis**

3–5 days after establishment of DRG cultures, AMPK activator treatments were administered to assess acetyl-CoA carboxylase (ACC) phosphorylation. Cells were treated with drug concentrations applied from 10x stocks in DMEM F-12 plus GlutaMax, including FBS and Pen-Strep. Following treatment, cells were fixed in ice cold 10% formalin in phosphate-buffered saline (PBS) for 1 h. Cells were then washed with PBS and permeabilized in PBS containing 10% heat inactivated normal goat serum (NGS, Atlanta Biologicals) and 0.02% Triton X-100 (Sigma) in PBS for 30 min and then blocked in 10% NGS in PBS for at least 1 h. Following additional washes, primary antibody (p-ACC, Cell Signaling Technologies) was applied overnight at 4 °C and the next day appropriate secondary antibodies (goat anti rabbit – alexa fluor 488, Invitrogen) were applied for 1 h. After additional PBS washes, coverslips were mounted on slides with ProLong Gold anti-fade with DAPI (Invitrogen). Images were taken on an Olympus Fluoview FV1200 laser scanning confocal microscope and analyzed using the co-localization tool within Olympus’ FV software. The intensity of each channel was adjusted so that only areas that contained a strong signal of 488 nm and 405 nm were visible. This adjusted imaged contained distinct puncta that could then be counted and analyzed using Graphpad prism 7.01.

**Tissue histology**

To determine re-epithelialization, plantar skin was excised from the left hind paw of mice either 3 days or 7 days following plantar incision surgery. The skin was immediately cryoprotected and frozen in O.C.T compound (Fisher Scientific) and sectioned (20 μm) on cryostat. The sections were then fixed in formalin and immersed in 0.1% Hematoxylin Gill 2X (Fisher Scientific) for 3 min, washed in tap water, then immersed in 0.1% eosin for 3 min, and dehydrated through graded ethanol (Protocol from University of Michigan Center for Organogenesis). Finally sections were cover slipped with Permount (Fisher Scientific). The sections were imaged and the width of the gap between 2 epithelial edges was measured using an Olympus BX51 microscope.

**Statistical analysis**

Data are shown as means and the standard error of the mean (± SEM) of 6 animals per group for behavioral studies. EC₅₀’s ± SEM were calculated for in vitro DRG experiments. Graph plotting and statistical analysis used Graphpad Prism Version 7.01 (Graph Pad Software, Inc.). Statistical evaluation was performed by one- or two-way analysis of variance (ANOVA), followed by appropriate post hoc tests. The a priori level of significance at 95% confidence level was considered at p < 0.05.

**RESULTS**

**Topical resveratrol inhibits acute mechanical hypersensitivity and hyperalgesic priming induced by plantar incision**

We have previously demonstrated that a 10-μg local injection of resveratrol into the hindpaw following plantar incision inhibits incision-mediated mechanical hypersensitivity as well as hyperalgesic priming induced by incision. Though local resveratrol injections efficaciously blocked incision-induced allodynia, clinical translatability necessitates a route of administration which is convenient and causes minimal discomfort. To address this issue, we generated a resveratrol cream preparation to be applied topically. Lyophilized resveratrol was serially dissolved in polyethylene glycol 400 (PEG 400) and solid PEG ointment to achieve a final concentration of 2 mg/ml. Utilizing a mouse model of incision pain, we assessed if topical application of resveratrol can prevent development of mechanical hypersensitivity following surgery (Brennan et al., 1996; Pogatzki and Raja, 2003). All animals received a plantar incision on the left hindpaw. Resveratrol (100 μg in 50 μL) or vehicle was applied on the paw of the incision once immediately following incision; or twice, immediately following incision and 1-day following incision. All mice were maintained under anesthesia for 1 h during the application of the topical treatment. Mice with plantar incision that received vehicle displayed mechanical hypersensitivity lasting for at least 10 days. While a single application of topical resveratrol did not have a significant effect on acute mechanical hypersensitivity (Fig. 1A), applying resveratrol twice significantly attenuated mechanical hypersensitivity induced by incision (Fig. 1B). In this model, hyperalgesic priming can be revealed by an intraplantar injection of inflammatory mediator PGE₂ (100 ng/25 μL) in the left hindpaw, after the resolution of initial allodynia (Asiedu et al., 2011) following plantar incision. Topical application of resveratrol once, or twice, inhibited the development of hyperalgesic priming precipitated by hindpaw injection of PGE₂ following resolution of incision-induced mechanical hypersensitivity (Fig. 1C and D). Thus, topically applied resveratrol is capable of not only blocking acute mechanical hypersensitivity induced by plantar incision but it also attenuates the development of hyperalgesic priming. These results suggest that topical application of resveratrol can be an efficacious treatment for post-surgical mechanical hypersensitivity.

**Low doses of resveratrol inhibit hyperalgesic priming in a model of post-surgical pain**

A single application of topical resveratrol does not influence acute mechanical hypersensitivity to incision but blocks hyperalgesic priming. This suggests that...
AMPK activation at the time of injury is capable of inhibiting the development of persistent nociceptor plasticity even if it is not effective for pain in the acute phase. To test this in more detail we used local injections of resveratrol so we could more precisely control the dose of compound. We gave two injections, spaced by 24 h, of 1 or 3 μg of resveratrol around the surgery site. While both doses had no effect on acute mechanical hypersensitivity until at least 6 days after incision, we observed significant inhibition of hyperalgesic priming with the 3-μg dose of intraplantar resveratrol (Fig. 2A and B).

Metformin inhibits acute mechanical hypersensitivity and hyperalgesic priming induced by plantar incision

Another therapeutic opportunity for activating AMPK is metformin. Metformin is already clinically available, safe, inexpensive and a well-tolerated drug. Moreover, metformin has a different mechanism of action in activating AMPK than resveratrol and may have differential efficacy in modulation of downstream targets. Metformin is known to activate AMPK through multiple indirect mechanisms including inhibition of mitochondrial complex I, LKB1 stimulation (Shaw et al., 2005) and inhibition of AMP deaminase (Ouyang et al., 2011). Additionally, in contrast to resveratrol, metformin has an improved bioavailability and thus can be given systemically, which is the preferred route of administration in humans. Hence, we investigated if systemic application of metformin can prevent development of incision-induced mechanical hypersensitivity and hyperalgesic priming following incision. Animals received an incision on the left hindpaw. Metformin (30, 100, 150 or 200 mg/kg) or vehicle was injected IP for 4 days; starting 2 days prior to the surgery, the day of, and 1-day post surgery. Mice with incision that received
vehicle displayed long-lasting acute mechanical hypersensitivity as well as hyperalgesic priming following PGE2 lasting at least 24 h. In contrast, IP injection of a 200 mg/kg dose of metformin prevented both acute incision-induced mechanical hypersensitivity (Fig. 3A and B) and the development of hyperalgesic priming following PGE2 injection on day 14 (Fig. 3C and D). Interestingly, the 150 mg/kg dose was not effective in blocking acute incision-induced mechanical hypersensitivity (Fig. 3A and B); but did significantly block hyperalgesic priming (Fig. 3C and D) similar to observations with resveratrol local dosing where doses that had little effect on acute mechanical hypersensitivity were effective in blocking hyperalgesic priming.

Co-treatment with low doses of systemic metformin and local resveratrol inhibits acute mechanical hypersensitivity and hyperalgesic priming in a model of post-surgical pain

Although, various AMPK activators can independently attenuate the development of the incision-induced hypersensitivity and hyperalgesic priming at higher doses, an effective treatment strategy could be to utilize sub-efficacious doses of AMPK activators and investigate if the co-treatment is equally efficacious in attenuating acute hypersensitivity and blocking the development of hyperalgesic priming following plantar incision. This strategy could minimize unwanted side-effects of metformin which could occur at higher doses. The primary side effect of metformin is gastrointestinal disturbance and diarrhea but lactic acidosis can occur in rare instances. This strategy might also allow for lowering doses into ranges that are more commonly given to humans. For instance, metformin doses in humans are typically 1/10th of what is given to mice (e.g. 25 mg/kg) (Gong et al., 2012). Hence, we investigated if co-treatment of sub-efficacious doses of metformin and resveratrol (100 mg/kg and 1 µg or 150 mg/kg and 3 µg) could have additive effects on attenuating incision-induced mechanical hypersensitivity and development of hyperalgesic priming. Animals received a plantar incision on the left hindpaw and received treatment of vehicle, resveratrol or metformin alone or a co-treatment of metformin and resveratrol. Metformin (100 or 150 mg/kg) was injected IP for 4 days; starting 2 days prior to the incision and resveratrol (1 or 3 mg) was injected in the left hindpaw around the incision on the day of the incision and 24 h later. Mice with incision that received vehicle again displayed long-lasting acute mechanical hypersensitivity as well as hyperalgesic priming following PGE2. Mice which received co-treatments of individually sub-efficacious doses of metformin and resveratrol (100 mg/kg and 1 µg) displayed a significant improvement in recovery on day 10 (Fig. 4A) and the cumulative effect of the combined doses was significantly greater than the individual doses alone compared to their respective vehicle treatment experiments (Fig. 4B). Moreover, this combined dose effectively inhibited hyperalgesic priming compared to vehicle-treated mice (Fig. 4C). Metformin and resveratrol at 150 mg/kg and 3 µg, respectively, significantly reduced acute mechanical hypersensitivity starting at day 2 (Fig. 4D) and produced a large enhancement of effect versus single treatment with either compound (Fig. 4E). This combined treatment inhibited hyperalgesic priming (Fig. 4F), displaying a strong additive effect compared to giving the compounds alone. A summary of the mechanism of action of metformin and resveratrol to activate AMPK is shown in Fig. 4G (Owen et al., 2000;...
Importantly, these compounds are thought to have distinct mechanisms of action in activating AMPK in neurons. Co-treatment of isolated DRG neurons with metformin and resveratrol additively induces AMPK signaling

Our in vivo findings suggest a leftward shift in the dose–response for AMPK activation in producing alleviation of mechanical hypersensitivity but due to the different dosing routes for the compounds (resveratrol has very poor systemic bioavailability) this is hard to determine empirically. Therefore, we sought to examine AMPK activation via resveratrol and metformin individually and together on DRG neurons in culture. We assessed acetyl-CoA carboxylase (ACC) phosphorylation on serine 79 using a phospho-specific antibody characterized for immunocytochemistry (ICC). We observed a significant increase in p-ACC intensity with metformin at 10 mM and resveratrol starting at 20 μM when the compounds were incubated with DRG neurons for 1 h (Fig. 5A and B). When we combined metformin and resveratrol, we observed a significant leftward shift in the concentration response for the resveratrol + metformin group as identified by shifts in the EC50 as shown in Fig. 6. From these findings we conclude that metformin and resveratrol have at least additive effects on AMPK activation in DRG neurons which likely explain their ability to enhance each other’s effects on mechanical hypersensitivity in vivo.

AMPK activators have no adverse effect on wound healing after incision

An important consideration in these experiments is that AMPK activators reduce protein translation and may negatively influence wound healing. This effect would have a negative impact on their clinical utility for postsurgical pain (Velnar et al., 2009). To test if AMPK activa-
tors effect wound healing, we utilized either vehicle or maximal local doses of resveratrol (two local injections of 10 µg) or metformin (200 mg/kg, 4 IP doses) described in the previous experiments and assessed wound healing with Hematoxylin & Eosin (H & E) staining (Lai et al., 2009). Skin samples were excised 3 and 7 days after incision to assess healing and wound closure, respectively. For the animals treated with resveratrol, no differences were noted in the wound size between the resveratrol and vehicle-treated groups on Day 3 (Fig. 6A). By Day 7, the wound was completely closed in the animals in both groups receiving local vehicle or resveratrol (Fig. 6A). Similar results were obtained with systemic metformin (Fig. 6B). We find no evidence that AMPK activators negatively influence the wound healing processes following incision.

**DISCUSSION**

The experiments described above are relevant for the possible development of AMPK activators to attenuate mechanical pain amplification after surgery and block the
development of neuronal plasticity that increases the sensitivity of nociceptors to sub-threshold levels of inflammatory mediators. We show that both the application of topical resveratrol and systemic metformin inhibit surgery-induced mechanical hypersensitivity and hyperalgesic priming produced by plantar incision. The findings also show that at the lower end of the dosing range, local resveratrol and systemic metformin do not inhibit acute surgery-induced mechanical hypersensitivity, but significantly attenuate hyperalgesic

Fig. 5. Co-treatment of isolated DRG neurons with metformin and resveratrol exhibit additive effects on AMPK signaling. DRG neurons in culture taken from Male ICR mice were treated with vehicle, metformin, or resveratrol alone or metformin + resveratrol for 1 h at indicated concentrations. A) Phosphorylation of ACC (p-ACC) was assessed by confocal microscopy (green) and neuronal cell nuclei were stained with DAPI (blue). B) Images were processed and the mean fluorescence intensity of pACC was measured and graphed. One-way ANOVA was used to assess differences between the vehicle and treatment groups with Fisher’s LSD post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001 (N = 5–12 coverslips per group). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Fig. 6. AMPK activators do not effect wound healing in response to incision. All Animals received a plantar incision on the left hindpaw. Skin from the left hindpaw was excised 3 and 7 days after plantar incision and wound healing and closure was assessed using Hematoxylin & Eosin (H & E) staining. A) Resveratrol (10 µg) or vehicle was injected in the left hind paw on the day of the surgery and 1-day post surgery. There was no difference in wound size between the resveratrol- and vehicle-treated groups on Day 3. The wound was completely closed by Day 7 in both vehicle and resveratrol groups. B) Metformin (200 mg/kg) or vehicle was injected systemically for 4 consecutive days, starting 2 days prior to surgery, the day of surgery, and 1-day post surgery. No differences were noted in the wound size between the metformin- and vehicle-treated groups on Day 3. The wound was completely closed by Day 7 in animals from groups receiving vehicle or metformin. Differences between groups were assessed by two tailed student’s t-test. (N = 6 per group).
priming. This suggests that even at small doses these compounds may be effective in reducing the transition to a chronic pain state after surgery. Interestingly, co-treatment with sub-efficacious doses of local resveratrol and systemic metformin had a significant effect on acute mechanical hypersensitivity and inhibited hyperalgesic priming. Our in vitro experiments on DRG neurons indicate the combination of resveratrol and metformin activate AMPK in at least an additive fashion. These data add to a growing body of evidence that AMPK activation can inhibit the development of acute mechanical hypersensitivity resulting from injury (Melemedjian et al., 2011; Tillu et al., 2012a; Russo et al., 2013; Bullon et al., 2015; Ma et al., 2015; Song et al., 2015; Maixner et al., 2016; Ling et al., 2017), reduce the excitability of nociceptors (Melemedjian et al., 2011, 2013; Tillu et al., 2012a; Asiedu et al., 2017) and prevent the development of hyperalgesic priming (Price and Dussor, 2013; Price et al., 2015; Asiedu et al., 2016; Mejia et al., 2016). We conclude that topical resveratrol and co-treatment of various AMPK activators such as metformin are clinically relevant and could show utility as pain therapeutics in humans.

An interesting finding emerging from our work is that the level of drug needed to inhibit acute mechanical hypersensitivity is greater than that needed to attenuate the development of hyperalgesic priming. While we did not investigate the mechanisms through which this occurs, we speculate that it may be due to even a relatively small amount of AMPK activation in DRG nociceptors being sufficient to block changes in gene expression that are required to cause nociceptors to transition to a primed state. However, when these same low doses of resveratrol and metformin where combined together, co-treatment effectively inhibited acute surgery-induced mechanical hypersensitivity and prevented hyperalgesic priming. Co-treatment with these low doses was likely efficacious because the treatment strategy led to enhanced AMPK activation. This is supported by our in vitro experiments where we saw a strong shift to the left in the concentration–response curve, as well as an increase in the magnitude of AMPK activation with combined metformin and resveratrol treatment.

We conducted experiments with metformin and resveratrol because these drugs can be used in humans immediately. Metformin is used for type 2 diabetes and is the most widely prescribed drug in the world. A previous study suggested that metformin may be effective for low back pain (Taylor et al., 2013) but a subsequent retrospective study did not find a positive effect for metformin in pain patients (Smith and Ang, 2015). The first prospective study of metformin for pain was recently conducted in women with polycystic ovary syndrome (Kialka et al., 2016). This study found a positive effect of metformin on pressure pain thresholds. A possible confound of translating preclinical work on metformin for pain, which includes a growing number of studies, is that the dose that is used is much higher than typical dosing in humans. While direct comparisons are not possible without extensive drug metabolism work, our experiments suggest strategies for obtaining effects of metformin at lower doses (e.g. by combining with local resveratrol) (Labuzek et al., 2013; Bullon et al., 2016).

While metformin is very hydrophilic and has excellent systemic bioavailability, resveratrol is highly lipophilic and lacks good systemic bioavailability. This makes resveratrol an ideal candidate for local or even topical application. Indeed, we found that topical resveratrol, in a very simple cream formulation, is effective in reducing incision-evoked mechanical hypersensitivity and that local resveratrol, when combined with systemic metformin at low doses, produces a reduction in acute post-surgical mechanical hypersensitivity and prevents the development of hyperalgesic priming. Because we found no adverse effects on wound healing of any of these drugs, this suggests a viable strategy for the translation of these findings into human patients. In this regard it is notable that resveratrol is generally regarded as safe by the United States Food and Drug Administration. It is notable that resveratrol and metformin seem to activate AMPK via different mechanisms. In neurons, resveratrol does not alter AMP/ATP ratios but activates the upstream kinase LKB1 to increase AMPK phosphorylation (Dasgupta and Milbrandt, 2007). Metformin increases cellular AMP levels via two mechanisms, inhibition of mitochondrial complex I (Owen et al., 2000) and inhibition of AMP deaminase (Ouyang et al., 2011). The consequences of these two drugs would be activation of AMPK by allosteric site binding with AMP and increased kinase activity by phosphorylation of the α subunit of AMPK. This strategy has been used with other drug combinations to synergistically activate AMPK (Ducommun et al., 2014). Our behavioral experiments show an indication of additive effects of combining resveratrol and metformin and our in vitro experiments show a clear, strong leftward shift in the concentration–response curve for the combined exposure. We were not able to formally assess synergism in either experimental paradigm due to different dosing routes for in vivo experiments and the very small efficacious concentration range of metformin in vitro.

Our work suggests that topical application of resveratrol at sites of surgery can reduce post-surgical mechanical hypersensitivity and prevent the development of hyperalgesic priming (Reichling and Levine, 2009; Kandasamy and Price, 2015; Price and Inyang, 2015). As persistent pain after surgery remains a major clinical problem (Kehlet et al., 2006), our work indicates that resveratrol may be used advantageously via topical application in this setting. We conclude that 1) topical treatment of resveratrol presents a low-risk readily usable therapeutic avenue, 2) sufficient dosing of systemic metformin attenuates both acute surgery-induced mechanical hypersensitivity and hyperalgesic priming and 3) co-treatment of resveratrol and metformin has an additive effect which activates AMPK in sensory neurons in vitro (4) leading to inhibition of surgery-induced mechanical hypersensitivity and the development of hyperalgesic priming in vivo. This creates multiple opportunities to further develop activators of AMPK as potential therapeutics for post-surgical pain.
Acknowledgments—This work was supported by National Institutes of Health grants R01GM102575 (TJP and GD), R01NS065926 (TJP) and The University of Texas STARS program research support grant (TJP and GD).

TJP and GD are co-founders of CERSCI Therapeutics and Ted’s Brain Science, biotechnology companies developing AMPK activators for the treatment of pain. The authors declare no other conflicts of interest.

REFERENCES


Tillu DV, Melemedjian OK, Asiedu MN, Qu N, De Felice M, Dussor G, Price TJ (2012a) Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain. Molecular Pain 8:5.

Tillu DV, Melemedjian OK, Asiedu MN, Qu N, De Felice M, Dussor G, Price TJ (2012b) Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain. Mol Pain 8:5.


(Received 6 May 2017, Accepted 10 July 2017)
(Available online 17 July 2017)